Jutamas Shaughnessy to Antibodies, Monoclonal
This is a "connection" page, showing publications Jutamas Shaughnessy has written about Antibodies, Monoclonal.
Connection Strength
0.116
-
Foss S, Sakya SA, Aguinagalde L, Lustig M, Shaughnessy J, Cruz AR, Scheepmaker L, Mathiesen L, Ruso-Julve F, Anthi AK, Gj?lberg TT, Mester S, Bern M, Evers M, Bratlie DB, Michaelsen TE, Schlothauer T, Sok D, Bhattacharya J, Leusen J, Valerius T, Ram S, Rooijakkers SHM, Sandlie I, Andersen JT. Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria. Nat Commun. 2024 Mar 07; 15(1):2007.
Score: 0.041
-
Gulati S, Pennington MW, Czerwinski A, Carter D, Zheng B, Nowak NA, DeOliveira RB, Shaughnessy J, Reed GW, Ram S, Rice PA. Preclinical Efficacy of a Lipooligosaccharide Peptide Mimic Candidate Gonococcal Vaccine. mBio. 2019 11 05; 10(6).
Score: 0.030
-
Gulati S, Beurskens FJ, de Kreuk BJ, Roza M, Zheng B, DeOliveira RB, Shaughnessy J, Nowak NA, Taylor RP, Botto M, He X, Ingalls RR, Woodruff TM, Song WC, Schuurman J, Rice PA, Ram S. Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody. PLoS Biol. 2019 06; 17(6):e3000323.
Score: 0.029
-
Beernink PT, Shaughnessy J, Ram S, Granoff DM. Impaired immunogenicity of a meningococcal factor H-binding protein vaccine engineered to eliminate factor h binding. Clin Vaccine Immunol. 2010 Jul; 17(7):1074-8.
Score: 0.016